Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Flonext S R L has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are split between 2 distinct examiners, with each examiner handling a single action. CHEN, PO-CHIH is the busiest examiner, holding 1 busiest examiner pending action.
The prosecution activity is spread across 2 distinct art units. This indicates that the pending office actions involve different technical sub-specialties within the Biotechnology & Pharmaceuticals field. With 2 distinct art units, the applicant must manage two separate prosecution paths simultaneously.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
| CHEN, PO-CHIH | 1 | 74.3% | +14.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18567877 | TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE RETINAL DISEASES | NEAGU, IRINA | — |
| 18567807 | PYRAZOLONE COMPOUNDS FOR USE IN DEGENERATIVE RETINAL DISEASES | CHEN, PO-CHIH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18567877 | TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE RETINAL DISEASES | NEAGU, IRINA | — |
| 18567807 | PYRAZOLONE COMPOUNDS FOR USE IN DEGENERATIVE RETINAL DISEASES | CHEN, PO-CHIH | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18567877 | TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE RETINAL DISEASES | NEAGU, IRINA | 1629 | §103§112 | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18567807 | PYRAZOLONE COMPOUNDS FOR USE IN DEGENERATIVE RETINAL DISEASES | CHEN, PO-CHIH | 1621 | §102§103§112 | Non-Final OA | — | Pending | Dec 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFlonext S R L has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Irina Neagu has the most, with 1 of Flonext S R L's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
